BioCentury
ARTICLE | Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

July 6, 2018 4:43 PM UTC

Neovacs S.A. (Euronext:ALNEV) plans to start Phase III testing of lupus candidate IFNalpha-Kinoid despite reporting mixed data from a Phase IIb trial in the indication. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha.

The therapy met one of the double-blind, international study's two primary endpoints. IFNalpha-Kinoid failed to significantly improve British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at week 36 vs. placebo, but did significantly reduce the expression of IFN-induced genes at week 36 vs. placebo (p<0.0001)...

BCIQ Company Profiles

Neovacs S.A.

BCIQ Target Profiles

Interferon (IFN) alpha